Teva Pharmaceutical Industries (TEVA) Notes Payables (2009 - 2017)

Teva Pharmaceutical Industries has disclosed Notes Payables across 7 years of filings, most recently posting $1.0 million for Q4 2017.

• Quarterly Notes Payables fell 93.33% year-over-year to $1.0 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $1.0 million (down 93.33% YoY) and the FY2017 annual result came in at $1.0 million, down 93.33% from the prior year.
• Notes Payables declined to $1.0 million in Q4 2017, from $15.0 million in the prior quarter.
• Over five years, Notes Payables peaked at $75.0 million in Q4 2015 and troughed at $1.0 million in Q4 2017.
• A 4-year average of $34.2 million and a median of $30.5 million in 2014 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2015 — Notes Payables surged 63.04% — and 2017, when it tumbled 93.33%.
• Tracing TEVA's Notes Payables over 4 years: stood at $46.0 million in 2014, then jumped by 63.04% to $75.0 million in 2015, then sank by 80.0% to $15.0 million in 2016, then slumped by 93.33% to $1.0 million in 2017.
• Business Quant data shows TEVA's Notes Payables at $1.0 million in Q4 2017, $15.0 million in Q4 2016, and $75.0 million in Q4 2015.